NZ200594A - Naftidrofuryl citrate and pharmaceutical compositions - Google Patents

Naftidrofuryl citrate and pharmaceutical compositions

Info

Publication number
NZ200594A
NZ200594A NZ200594A NZ20059482A NZ200594A NZ 200594 A NZ200594 A NZ 200594A NZ 200594 A NZ200594 A NZ 200594A NZ 20059482 A NZ20059482 A NZ 20059482A NZ 200594 A NZ200594 A NZ 200594A
Authority
NZ
New Zealand
Prior art keywords
naftidrofuryl
citrate
oxalate
naftidrofuryl citrate
properties
Prior art date
Application number
NZ200594A
Other languages
English (en)
Inventor
C Blasioli
J A Chick
A Heymes
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9258433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ200594(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NZ200594A publication Critical patent/NZ200594A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ200594A 1981-05-14 1982-05-13 Naftidrofuryl citrate and pharmaceutical compositions NZ200594A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8109590A FR2505836A1 (fr) 1981-05-14 1981-05-14 Citrate de naftidrofuryl et son application therapeutique

Publications (1)

Publication Number Publication Date
NZ200594A true NZ200594A (en) 1985-03-20

Family

ID=9258433

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ200594A NZ200594A (en) 1981-05-14 1982-05-13 Naftidrofuryl citrate and pharmaceutical compositions

Country Status (22)

Country Link
US (1) US4439442A (cg-RX-API-DMAC10.html)
EP (1) EP0065446B1 (cg-RX-API-DMAC10.html)
JP (1) JPS57203078A (cg-RX-API-DMAC10.html)
KR (1) KR830010091A (cg-RX-API-DMAC10.html)
AT (1) ATE9342T1 (cg-RX-API-DMAC10.html)
AU (1) AU8373282A (cg-RX-API-DMAC10.html)
CA (1) CA1184562A (cg-RX-API-DMAC10.html)
CS (1) CS239923B2 (cg-RX-API-DMAC10.html)
DD (1) DD202432A5 (cg-RX-API-DMAC10.html)
DE (1) DE3260712D1 (cg-RX-API-DMAC10.html)
DK (1) DK210982A (cg-RX-API-DMAC10.html)
ES (1) ES8304559A1 (cg-RX-API-DMAC10.html)
FI (1) FI821664A7 (cg-RX-API-DMAC10.html)
FR (1) FR2505836A1 (cg-RX-API-DMAC10.html)
GR (1) GR75422B (cg-RX-API-DMAC10.html)
HU (1) HU187701B (cg-RX-API-DMAC10.html)
IL (1) IL65774A (cg-RX-API-DMAC10.html)
NZ (1) NZ200594A (cg-RX-API-DMAC10.html)
PT (1) PT74893B (cg-RX-API-DMAC10.html)
SU (1) SU1082323A3 (cg-RX-API-DMAC10.html)
YU (1) YU103082A (cg-RX-API-DMAC10.html)
ZA (1) ZA823195B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104086515A (zh) * 2014-06-13 2014-10-08 刘博� 萘呋胺酯草酸盐的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2580502B1 (fr) * 1985-04-23 1988-07-08 Lipha Emploi du " naftidrofuryl " dans la preparation d'un medicament
TW200920348A (en) * 2007-06-28 2009-05-16 Dybly Ag Combination of picotamide with nafronyl
US8203109B2 (en) 2009-05-08 2012-06-19 Raytheon Company High energy laser beam director system and method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL142872C (cg-RX-API-DMAC10.html) * 1963-03-28
FR3843M (fr) * 1964-03-17 1966-01-17 Lipha Nouvelles bases azotées a propriétés antispasmodique et vasodilatatrice.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104086515A (zh) * 2014-06-13 2014-10-08 刘博� 萘呋胺酯草酸盐的制备方法

Also Published As

Publication number Publication date
AU8373282A (en) 1982-11-18
FI821664A0 (fi) 1982-05-11
YU103082A (en) 1984-08-31
GR75422B (cg-RX-API-DMAC10.html) 1984-07-16
ATE9342T1 (de) 1984-09-15
IL65774A (en) 1985-09-29
HU187701B (en) 1986-02-28
US4439442A (en) 1984-03-27
ES512819A0 (es) 1983-03-01
DD202432A5 (de) 1983-09-14
CA1184562A (fr) 1985-03-26
FR2505836A1 (fr) 1982-11-19
SU1082323A3 (ru) 1984-03-23
EP0065446A1 (fr) 1982-11-24
ZA823195B (en) 1983-03-30
DK210982A (da) 1982-11-15
CS239923B2 (en) 1986-01-16
PT74893A (fr) 1982-06-01
FI821664L (fi) 1982-11-15
ES8304559A1 (es) 1983-03-01
KR830010091A (ko) 1983-12-26
FR2505836B1 (cg-RX-API-DMAC10.html) 1984-03-09
JPS57203078A (en) 1982-12-13
DE3260712D1 (en) 1984-10-18
PT74893B (fr) 1983-12-23
FI821664A7 (fi) 1982-11-15
EP0065446B1 (fr) 1984-09-12
US4439442B1 (cg-RX-API-DMAC10.html) 1987-06-30
IL65774A0 (en) 1982-08-31

Similar Documents

Publication Publication Date Title
Kumar et al. Experimental myocardial infarction: VI. Efficacy and toxicity of digitalis in acute and healing phase in intact conscious dogs
US4066678A (en) 3-trihydroxygermyl propionic acid and its salts and a process for the production thereof
US4749707A (en) Citric acid salt of (+) vinpocetine
JPWO1999020620A1 (ja) イソキノリン誘導体及び医薬
Singh et al. Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine
JPS6217972B2 (cg-RX-API-DMAC10.html)
JP7498504B2 (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
US4439442A (en) Naftidrofuryl citrate and therapeutic applications
JPS6043351B2 (ja) 老人医学的薬剤の製法
FI79526B (fi) Foerfarande foer framstaellning av de optiska antipoderna av ( )-1,7-difenyl-3-metylaza-7-cyan-8-metyl- nonan, vilka aer terapeutiskt anvaendbara.
Wollam et al. Acute hemodynamic effects and cardioselectivity of acebutolol, practolol, and propranolol
SU1598870A3 (ru) Способ получени производных 1,4-дигидропиридина
WO1994005290A1 (fr) Inhibiteur d'agregation plaquettaire
JPH02108688A (ja) キノリン化合物
US4814336A (en) Method of treating a vascular obstructive lesion resulting from restricted blood circulation
Doxey Tolmesoxide, a drug that lowers blood pressure by a direct relaxant effect on vascular smooth muscle
JPS63208525A (ja) 心不全治療剤
US20150197537A1 (en) Hydroxysafflor Yellow Pharmaceutical Salts
KR100256867B1 (ko) 엘-무스콘의 의약용도
EP0075029B1 (en) Agent for treating chronic obliterative lung disease
US4107172A (en) Uricosuric diuretic composition
US5747495A (en) Method for treating hypertension using pyrazolopyrimidine derivatives
US4678796A (en) 2-alkylidene derivatives of 1,2,3,4-tetrahydropyridine-2,5-pyridine carboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
JP2636265B2 (ja) 脳循環改善剤
JP3247763B2 (ja) キサンチン誘導体からなる血液循環の中断による神経損傷の治療用医薬